Polycomb deficiency drives a FOXP2-high aggressive state targetable by epigenetic inhibitors

Inhibitors of the Polycomb Repressive Complex 2 (PRC2) histone methyltransferase EZH2 are approved for certain cancers, but realizing their wider utility relies upon understanding PRC2 biology in each cancer system. Using a genetic model to delete Ezh2 in KRAS-driven lung adenocarcinomas, we observe...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Fan, Byrd, Aria L., Liu, Jinpeng, Flight, Robert M., DuCote, Tanner J., Naughton, Kassandra J., Song, Xiulong, Edgin, Abigail R., Lukyanchuk, Alexsandr, Dixon, Danielle T., Gosser, Christian M., Esoe, Dave-Preston, Jayswal, Rani D., Orkin, Stuart H., Moseley, Hunter N. B., Wang, Chi, Brainson, Christine Fillmore
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9859827/
https://www.ncbi.nlm.nih.gov/pubmed/36670102
http://dx.doi.org/10.1038/s41467-023-35784-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9859827/
https://www.ncbi.nlm.nih.gov/pubmed/36670102
http://dx.doi.org/10.1038/s41467-023-35784-x

Ejemplares similares